The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: A descriptive study

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 9, 2006, Pages 675-682

  Meijer, Willemijn M ^a   Cornel, Martina C ^b   Dolk, Helen ^c   de Walle, Hermien E K ^d   Armstrong, Nicola C ^e,i   de Jong van den Berg, Lolkje T W ^a,f   Abramsky, Lenore ^g   Addor, Marie Claude ^h   Baena, Neus ^j   Bakker, Marian ^j   Barisic, Ingeborg ^j   Bianca, Sebastiano ^j   Boyd, Patricia ^k   De Vigan, Catherine ^j   Draper, Elizabeth ^j   Garne, Ester ^j   Gatt, Miriam ^j   Gener, Blanca ^l   Haeusler, Martin ^j   Irgens, Lorentz ^j   Jordan, Hilary ^j   Loane, Maria ⁱ   O'Mahony, M T ^m   Martínez Frías, Maria Luisa ⁿ   Berjemo, Eva ⁿ   Mc Donnel, Bob ^j   Nelen, Vera ^j   Neville, Amanda ^o   Clabrese, Olga ^o   Rivieri, Francesca ^o   Pierini, Anna ^j   Bianchi, Fabrizio ^j   Riaño Galán, Isolina ^j   Ritvanen, Annukka ^p   Robert Gnansia, Elisabeth ^q   Stoll, Claude ^j   Soares, Maria ^j   Tenconi, Romano ^j   Wellesley, Diana ^j   Wiesel, Awi ^j   more..

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ULSTER   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Research and Development Office for Health and Personal Social Services in Northern Ireland   (United Kingdom)

^f Antonius Deusinglaan 1   (Netherlands)

^g North Thames   (United Kingdom)

^h Service de Genetique Medicale   (Switzerland)

ⁱ EUROCAT Central Registry   (United Kingdom)

^j Registry of Congenital Anomalies of the Basque Country ^*

^k OXCAR   (United Kingdom)

^l Registry of Congenital Anomalies of the Basque Country   (Spain)

^m IMER Registry ^*  (Ireland)

ⁿ ECEMC   (Spain)

^o IMER Registry   (Italy)

^p NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^q Central East France   (France)

more..

Author keywords

Congenital anomalies; Drug exposure; Post marketing surveillance; Pregnancy

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTITHYROID AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; ESTROGEN; FIBRINOLYTIC AGENT; GESTAGEN; HYPNOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOCAL ANESTHETIC AGENT; METHYLXANTHINE DERIVATIVE; ORAL ANTIDIABETIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SPASMOLYTIC AGENT; UNINDEXED DRUG; UTERUS SPASMOLYTIC AGENT; VACCINE;

ARTICLE; CONGENITAL MALFORMATION; DATA BASE; DESCRIPTIVE RESEARCH; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMATION PROCESSING; INTERVIEW; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; TERATOGENICITY;

EID: 33748805989     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1265     Document Type: Article

References (25)

1. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 2005; 90: F355-F358.
2. www.eurocat.ulster.ac.uk EUROCAT 'home page'.
3. International Clearinghouse for Birth Defects Monitoring Systems. Annual Report 2001 with data for 1999. The International Centre for Birth Defects, Rome, 2002.
4. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203-215.
5. Cornel MC, Erickson JD, Khoury MJ, James LM, Liu Y. Population-based birth defect and risk-factor surveillance: data from the Northern Netherlands. Int J Risk Saf Med 1996; 8: 197-209.
6. Reethuis J, Zandwijken GRJ, de Walle HEK, Cornel MC. Birth defect and risk factor surveillance in the Northern and Southwestern Netherlands. Community Genet 1999; 2: 97-108.
7. Robert E, Vollset SE, Botto L, et al. Malformation surveillance and maternal drug exposure; the MADRE project. Int J Risk Saf Med 1994; 6: 75-118.
8. De Wals P, Bloch D, Calabro A, et al. Association between holoprosencephaly and exposure to topical retinoids: results of the EUROCAT Survey. Paediatr Perinat Epidemiol 1991; 5(4): 445-447.
9. Dolk H. Methylene blue and atresia or stenosis of ileum and jejunum. EUROCAT working Group. Lancet 1991; 338: 1021-1022.
10. Kroes HY, Reethuis J, Cornel MC. Is there an association between maternal carbamazepine use during pregnancy and eye malformations in the child? Epilepsia 2002; 43(8): 929-931.
11. Queisser-Luft A, Eggers I, Stolz G, Kieninger-Baum D, Schlaefer K. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. Am J Med Genet 1996; 63: 268-276.
12. Martínez-Frías ML, Rodríguez-Pinilla E. Epidemiologic analysis of prenatal exposure to cough medicines containing dextromethorphan: No evidence of human teratogenicity. Teratology 2001; 63: 38-41.
13. Malm H, Martikainen J, Klaukka T, Neuvonen P. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol 2003; 59: 127-133.
14. EUROCAT Guide 1.2: Instructions for the Registration of Congenital Anomalies. EUROCAT Central Registry, University of Ulster, 2002. (http://www.eurocat.ulster.ac.uk/pdf/guide1_2.pdf).
15. EUROCAT Working Group. EUROCAT Report 8: Surveillance of congenital anomalies in Europe 1980-99. University of Ulster, 2002. (http://www.eurocat.ulster.ac.uk/pubdata/report8.html).
16. De Vries CS, De Walle HEK, Cornel MC, De Jong-van den Berg LTW. Registration of drug use in a birth defect monitoring system: a priority worthy of emphasis! Int J Risk Saf Med 1993; 4: 27-34.
17. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Teratology 1999; 60: 33-36.
18. Reethuis J, de Walle HE, de Jong-van den Berg LT, Cornel MC. Additional information from parental questionnaires and pharmacy records for registration of birth defects. EuroMAP-group. Eur J Epidemiol 2000; 16: 329-336.
19. De Vigan C, de Walle HEK, Cordier S, et al. Therapeutic drug use druring pregnancy: a comparison in four European countries. J Clin Epidemiol 1999; 52(10): 977-982.
20. Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LTW. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. EJOGR 2004; 114: 182-188.
21. Irl C, Kipferler P, Hasford J. Drug use assessment and risk evaluation in pregnancy - the PEGASUS-Project. Pharmacoepidemiology and Drug Safety 1997; 6 (Suppl. 3):S37-S42.
22. Olesen C, Sorensen HT, de Jong-van den Berg LTW, Olsen J, Steffesen FH, and The Euromap Group. Prescribing during pregnancy and lactation with reference to the swedish classification system. A population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686-692.
23. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC classification and DDD asignment. Oslo: WHO; 1999.
24. Källén B, Castilla EE, Robert E, et al. An international case-control study on hypospadias. The problem of variability and the beauty of diversity. Eur J Epidemiol 1992; 8: 256-263.
25. Garcia Rodriquez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiologyl. Br J Clin Pharmacol 1998; 45: 419-425.